Oncolytics Biotech Stock Soars 13.08% on Earnings Outlook

Oncolytics Biotech's stock surged by 13.08% in pre-market trading on August 29, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Analysts have set a range of price targets for Oncolytics Biotech, with the highest target at $7.00 and the lowest at $3.00. The average price target suggests a potential upside of 367.29%, indicating strong optimism about the company's future prospects.

Oncolytics Biotech is expected to see a decrease in earnings for the coming year, with projections moving from ($0.28) to ($0.30) per share. This earnings outlook may influence investor sentiment and stock performance in the near term.

The company recently announced its participation in upcoming investor conferences, which could provide additional insights into its strategic direction and future plans. This engagement with the investment community is likely to generate further interest and potentially drive stock price movements.

Oncolytics Biotech has also announced its delisting from the Toronto Stock Exchange, which may impact its trading dynamics and investor base. This move could streamline its operations and focus on its primary listing on the NASDAQ.

Additionally, the company is advancing toward a registration-enabling trial for its immunotherapy treatments, which could be a game-changer in the cancer treatment landscape. This development underscores Oncolytics Biotech's commitment to innovation and its potential to revolutionize the field of oncology.